Estimación de la diversidad genética de Anadara tuberculosa en cinco manglares de Tumaco, utilizando la enzima citocromo oxidasa I

ABSTRACTObjective. To estimate the genetic diversity of the Anadara tuberculosa en five mangrove swams of Tumaco, Nariño, Colombia using as a mitocondrial molecular marker the cytochromo oxidase sub-unit I (COI). Materials and methods. A total of 50 individuals were collected from the San Jorge, La Tiburonera, El Pajal, La Playa y Bajito Vaquería mangrove swamps, randomly selecting 10 specimens of each zone. The tissue sample was worked with absolute alcohol at ambient temperature in microtubes. DNA was extracted, and the mitocondrial DNA was amplified using the PCR technique (polymerase chain reaction). The amplified and quantified products of PCR were sequenced on both sides (Macrogen). Each one of the obtained sequences was edited and aligned. Later, the parameters of genetic diversity (haplotypical and nucleotidical) were measured, and the analysis of distribution between frequency pairs (Mistmach distribution) was elaborated. Finally, the analysis of nucleotidic variation and population structure (AMOVA) was completed. Results. The amplified product gene weighed 710 bp. The haplotypical diversity reported for all the populations was high (0.683±0.060) and the reported nucleotídical diversity was low for all the populations (0.040±0.020). The AMOVA results indicate that the variance amongst populations is low (4.20%) and that the variance within populations is high (95.80%). Conclusions. The studied populations are not structured and although there is a decrease of natural banks, the genetic diversity is high.RESUMENObjetivo. Estimar la diversidad genética de Anadara tuberculosa en cinco manglares de Tumaco Nariño, Colombia utilizando como marcador molecular mitocondrial la subunidad I de la citocromo oxidasa (COI). Materiales y métodos. Se colectaron en total 50 individuos de los manglares San Jorge, La Tiburonera, El Pajal, La Playa y Bajito Vaquería, tomando 10 ejemplares al azar de cada  extrajo y amplificó el ADN mitocondrial mediante la técnica de PCR (Polymerase Chain Reaction). Los productos de PCR amplificados y cuantificados se secuenciaron por ambos lados (Macrogen). Una vez se obtuvo las secuencias, se editó y alineo cada secuencia. Posteriormente, se midió los parámetros de diversidad genética (haplotípica y nucleotídica) y se elaboró el análisis de distribución entre pares de frecuencias (Mistmach distribution). Finalmente se efectuó el análisis de variación nucleotídica y la estructura poblacional (AMOVA). Resultados. El gen amplificado tuvo una longitud de 710 pb. La diversidad haplotípica reportada para todas las poblaciones fue alta (0.683±0.060) y la diversidad nucleotídica reportada fue baja para todas las poblaciones (0.040±0.020). Los resultados del AMOVA indican que la varianza entre poblaciones es baja (4.20%) y la varianza dentro de las poblaciones es alta (95.80%). Conclusiones. Las poblaciones estudiadas no se encuentran estructuradas y a pesar de la disminución de los bancos naturales de las poblaciones de Anadara tuberculosa, se estima que la diversidad genética es alta

Comparación de metodologías moleculares para identificar el gen de la kappa caseína en ganado Holstein

RESUMENObjetivo. Comparar las metodologías moleculares, PCR-RFLPs y PCR-SSCP, para identificar las variantes alélicas del gen de la kappa caseína (CSN3) en bovinos Holstein del trópico alto de Nariño-Colombia. Materiales y métodos. Se escogieron al azar 50 vacas Holstein y mediante punción en la vena coxígea media se tomaron muestras de 5cc de sangre, que se almacenaron y preservaron en tarjetas FTA® para su posterior análisis en el laboratorio. El ADN se amplificó por PCR utilizando cebadores específicos. Los cambios en la conformación de cadena sencilla (SSCP) fueron visualizados en geles de poliacrilamida al 12%; mientras que los RFLPs se obtuvieron por digestión con tres enzimas de restricción y se visualizaron en geles de agarosa al 4%. Resultados. La metodología PCR-RFLPs fue útil para detectar mutaciones puntuales y por lo tanto se identificó un mayor número de alelos, lo que contribuye a una mejor estimación de las medidas de diversidad genética en poblaciones seleccionadas, ya que evita problemas de sobreestimación de los valores en las frecuencias alélicas. Por su parte, la técnica PCR-SSCP resultó más sencilla y económica, ideal para investigaciones en las que no existe información previa sobre los genotipos de las poblaciones bovinas y en estudios con bajos presupuestos. Conclusiones. Las dos metodologías evaluadas son herramientas moleculares que contribuyen a la orientación de los procesos de selección en los bovinos para leche, ya que identifican los alelos del gen CSN3. La diferencia radica en el costo de las mismas y en el número de variantes identificadas

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years